Navigation Links
University of Maryland researchers discover possible drug targets for common non-Hodgkin's lymphoma
Date:7/19/2011

Baltimore, MD July 19, 2011. Researchers at the University of Maryland School of Medicine have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma.

In a study published online in Nature Communications, the scientists report that they have found a complex molecular and functional relationship between ERK (extracellular signal-regulated kinase), a protein that helps to regulate cell proliferation and survival, and CHK2 (checkpoint kinase 2), a protein that is involved in the cellular DNA damage response. They also demonstrated, for the first time, elevated levels of both proteins in diffuse large B-cell lymphoma cells, compared to non-cancerous cells.

Ronald B. Gartenhaus, M.D., associate professor of medicine at the University of Maryland School of Medicine and the senior author, says researchers found that CHK2 appears to regulate the activity of ERK, although the exact mechanism is not clear. "The two proteins physically interact, which was not known before, and we may be able to use this interaction for therapeutic advantage. We found that treating human B-cell lymphoma cells with both an ERK inhibitor inhibitor and a CHK2 inhibitor killed substantially more cancer cells than treating the cells with either drug alone," he says.

"Based on our findings, we believe that a combination therapy targeting both ERK and CHK2 could offer a potential new approach to treating diffuse large B-cell lymphoma," says Dr. Gartenhaus, who is co-leader of the Program in Molecular and Structural Biology at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.

The drugs used to inhibit ERK and CHK2 caused the cancer cells to die through a process called apoptosis, or programmed cell death. Human cells normally self-destruct in a controlled manner, but cancer cells lose this ability and consequently grow uncontrollably.

E. Albert Reece, M.D., Ph.D., M.B.A., vice president of medical affairs at the University of Maryland and dean of the University of Maryland School of Medicine, says, "This is a very important discovery that may ultimately benefit patients with diffuse large B-cell lymphoma, a common hematological malignancy that can be difficult to treat. These findings provide valuable new insight into the molecular make-up of this cancer that may lead to new targeted drug therapies."

Lymphoma is a cancer that originates in the lymphocytes (a type of white blood cell) of the immune system. Diffuse large B-cell lymphoma is a fast-growing, aggressive form of non-Hodgkin's lymphoma. It accounts for about 30 to 35 percent of all non-Hodgkin's lymphomas, and about 25,000 new cases are diagnosed each year. Non-Hodgkin's lymphomas usually are treated with several types of chemotherapy cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) and a biological therapy, such as the monoclonal antibody rituximab (Rituxan). Radiation therapy may be used on occasion, and bone marrow or stem cell transplantation may also be a treatment option.

Dr. Gartenhaus says researchers hope the study findings will help to develop new therapies that will be effective and well-tolerated by patients. "We believe it is important to identify drugs that can improve the efficacy and reduce the toxicity of standard anti-lymphoma therapy," he says.

The new research showed that using compounds to inhibit ERK and CHK2 did not cause any significant damage to normal cells or tissue examined in the lab, according to Bojie Dai, Ph.D., a postdoctoral fellow at the University of Maryland School of Medicine and the lead author. "We hope that new therapies directed at these two proteins would have modest side effects because they would target only the lymphoma cells," Dr. Dai says.

Dr. Gartenhaus says that researchers don't know yet whether the interaction between ERK and CHK2 occurs in other types of lymphoma.


'/>"/>

Contact: Karen E. Warmkessel
kwarmkessel@umm.edu
410-328-8919
University of Maryland Medical Center
Source:Eurekalert

Related medicine news :

1. Columbia University Medical Center receives $38.9 million to help translate science into treatment
2. Wayne State University engineering student receives American Tinnitus Association award
3. Mainz University Medical Center deploys new system for therapy of metastatic spinal tumors
4. Wayne State University researcher argues that sex reduces genetic variation
5. New book by Indiana University physicians slays health myths we all thought were true
6. Health providers should emphasize breast cancer screening, Wayne State University research finds
7. Researchers at Oregon Health & Science University discover MS-like disease in monkeys
8. Religion benefits traumatic brain injury victims, Wayne State University research finds
9. Internationally recognized BME professor to join University of Texas as visiting scholar
10. Three senior Hebrew University faculty members receive Kaye Awards for innovations
11. Wayne State University researchers win grant from the NSF to target tinnitus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... ... Duane Boise, President and CEO of EMED, today signed a multifaceted agreement which ... EMED and the Northern Caribbean University Department of Natural and Applied Sciences, Allied ...
(Date:4/30/2016)... ... ... Orlando-based Maximized Living has selected Dr. Nick Wilson of Indianapolis to support ... care of Maximized Living doctors at the London Olympics in 2012, U.S. wrestlers won ... the largest contingent of elite chiropractors to Rio to support and care for members ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published April ... enthusiasm for Botox and lip injections, which she underwent in order to feel more ... Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona ... Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and ... products to the store is just one more way Shamangelic Healing supports people’s ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... our nation’s productivity, stability, even security. Most importantly, employees are the single most ... why are American workers so unhappy? , Just under half of American workers ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... BASEL , Schweiz, April 27, 2016 ... des Sachs CEO Forums in Zürich ... Phase-II-Studie ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung ... (CI) eingesetzt wurde, bekannt. Für die umfassende ... Deutschland und Frankreich angeworben. STR001 wird während ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
(Date:4/27/2016)... , April 27, 2016 ... initiative to save newborns   ... for women & newborns in collaboration with Breast Milk Foundation ... the first Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. ... nutritional food source for infants and should be available to ...
Breaking Medicine Technology: